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ABSTRACT  
Purpose: Focused ultrasound (FUS) is a modality with rapidly expanding applications across 
Medicine. Treatment of bone lesions with FUS including both benign and malignant tumors has 
been an active area of investigation. Recently, as a result of a successful phase III trial, magnetic 
resonance guided FUS is now a standardized option for treatment of painful bone metastases. 
This report reviews the clinical applications amenable to treatment with FUS and provides 
background on FUS and image guidance techniques, results of clinical studies, and future 
directions. 
Methods: A comprehensive literature search and review of abstracts presented at the recently 
completed 4
th
 International Focused Ultrasound Symposium was performed. Case reports and 
older publications revisited in more recent studies were excluded. For clinical studies that extend 
beyond bone tumors, only the data regarding bone tumors are presented. 
Results: Fifteen studies assessing the use of focused ultrasound in treatment of primary benign 
bone tumors, primary malignant tumors, and metastastic tumors meeting the search criteria were 
identified. For these clinical studies the responders group varied within 91-100%, 85-87% and 
64-94%, respectively. Major complications were reported in the ranges 0%, 0-28% and 0-4% for 
primary benign, malignant and metastatic tumors, respectively.  
Conclusions: Image-guided FUS is both safe and effective in the treatment of primary and 
secondary tumors. Additional phase III trials are warranted to more fully define the role of FUS 
in treatment of both benign and malignant bone tumors. 
Keywords: High-Intensity Focused Ultrasound, Ablation, Bone tumor, Pain palliation, Image 
guidance. 
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1. INTRODUCTION 
Bone tumors, whether benign or malignant, often present challenges with local disease control 
and pain. Several bone tumor clinical studies have been conducted in the last decade, focused on 
both curative and palliative treatments. One emerging modality in treatment of bone tumors is 
high intensity focused ultrasound (FUS), which causes thermal damage of tissue using focused 
sound waves. The FUS treatment is guided in real-time by magnetic resonance (MRgFUS) or 
ultrasonography (USgFUS), which provides a feedback mechanism to increase treatment 
accuracy. This technique is non-invasive and does not use ionizing radiation, which contrasts 
with standard approaches, such as surgery or radiotherapy, used in cancer treatment. The aim of 
this paper is to review bone tumor clinical studies using both USgFUS and MRgFUS, including 
benign tumors, primary malignancies, and metastatic bone tumors. 
The vast majority of primary bone tumors are benign. Many are asymptomatic and thus remain 
undetected until radiographic examinations are performed for other reasons. Thus, the actual 
incidence of benign bone tumors is currently indeterminate [1]. One of the most common is 
osteoid osteoma, comprising nearly 10% of benign bone tumors [2]. It consists of a nidus, or 
core of growing cells, surrounded by a thick bony shell that is normally found in the 
appendicular skeleton [3]. They are predominantly seen in children, teenagers, and young adults, 
with more than 80% of tumors seen in individuals between the ages of 5 and 30 years [4]. The 
presence of a benign bone lesion does not necessarily mean lack of aggressiveness; histologically 
benign lesions may be locally highly aggressive, causing severe discomfort and pain [5].  
Malignant primary bone tumors constitute 0.2% of all malignancies in adults and approximately 
5% of childhood malignancies [1]. The most common primary malignant bone tumor is 
osteosarcoma, representing 35% of total primary bone malignancies [6]. The 5-year overall 
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survival rate for bone sarcoma is 68%. Osteosarcomas usually develop in areas where the bone is 
growing quickly, such as near the ends of the long bones, and are most common in children and 
young adults. These particular tumors require aggressive local treatment and at times may 
require amputation. 
Bone metastases are the most common source of pain in cancer patients [7]. Autopsy studies 
have shown that up to 85% of patients with breast, prostate and lung cancer have bone 
metastases at the time of death. Complications due to skeletal metastases, including intractable 
pain, fracture, and decreased mobility, can dramatically reduce performance and quality of life 
and lead to depression and anxiety [8]. Bone metastases portend a poor prognosis, with patients 
generally facing a median survival of 3 years or less. In lung cancer, survival is typically 
measured in months, whereas patients with breast cancer or prostate cancer often live for several 
years. Bone metastases are generally classified as osteolytic which is characterized by 
destruction of normal bone or osteoblastic characterized by deposition of new bone. This 
distinction is not absolute since metastatic lesions can contain both osteolytic and osteoblastic 
components [9]. 
There are two distinct treatment approaches for bone tumors: curative and palliative. For thermal 
ablation techniques, in particular, curative treatment aims for complete coagulation necrosis of 
the primary lesion. In palliative treatment of primary or secondary bone tumors, therapeutic 
goals include pain palliation, tumor reduction, prevention of impending pathologic fractures, 
and/or tumor decompression. The denervation of the periosteum, which contains pain-reporting 
nerve fibers, is considered a major factor in pain palliation. This explains the rapid relief 
following ultrasound treatment which is characterized by enhanced power deposition in bone 
relative to surrounding soft tissues [10]. 
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Clinical applications of thermal ablation therapy are expanding rapidly due to the ability to 
produce immediate obliteration of either small tumors or benign disease, when the target volume 
is located in an anatomic region with sufficient biological reserve and/or separation from 
surrounding critical normal tissues. Either cryogenic temperatures (<-40C) or high temperatures 
>50-60C produce complete ablation of the tissue vasculature and most importantly disrupt and 
coagulate all structural proteins in the target cells. These effects are non-subtle and irreversible, 
leading to immediate and complete cellular death. In lower dose regions, in the transition zone of 
a thermally coagulated lesion, there is a percentage of cells that survive the thermal insult. In this 
border region, adjunctive therapies such as radiation or chemotherapy may be helpful in further 
expanding the radial penetration of effective therapy, by providing some differential effect on 
weaker tumor cells relative to the surrounding normal tissue host.  
There are numerous technologies available to produce a high intensity heat focus at depth in 
tissue. Invasive approaches include interstitial or intracavitary placement of radiofrequency 
(RFA), microwave (MWA), laser, or thermal conduction sources into the target region (Table I). 
These implantable heat sources are well-characterized in the literature [11-14], and for many 
tissue sites like liver, breast, prostate, kidney and lung, they can heat deep tissue targets 
effectively without unacceptable normal tissue complications [4, 15]. Insertion of heat sources 
directly into bone tissue is difficult however, such that a non-invasive approach with precise 
control of the focal zone at depth is required. Taking advantage of the short wavelength and deep 
penetration of ultrasound pressure waves, beams may be combined from large external 
transducer arrays to produce an intense focal hot spot at depth non-invasively; thus the name 
high intensity focused ultrasound (FUS).  
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2. METHODS  
This section reviews the FUS method, image guidance techniques, and FUS devices used in 
ongoing clinical studies. Furthermore, we address primary and secondary endpoints typical in the 
analyzed clinical studies as well as the tools for outcome assessment. 
2.1. High-Intensity Focused Ultrasound 
In general, ultrasound systems produce an acoustic pressure wave from one or more piezoelectric 
transducers that operate at a frequency in the range of 0.2-4 MHz. Attenuation of ultrasound 
energy as it propagates through biologic tissue results in a rise of temperature in the treated 
volume. Coagulative necrosis and cell death occur within seconds at temperatures in the range of 
65-85°C [16], so that the ablative treatment must be well localized to the tumor target and avoid 
surrounding normal tissues. To achieve the required focusing and rapid elevation of tissue 
temperature at depth, the ultrasound energy is usually intensified at a focal spot by using multiple 
intersecting ultrasound beams that converge on the target. Typical clinical focused ultrasound 
systems produce high intensity focal volumes of 0.2-20 mm
3 
at depth, while spreading out the 
ultrasound energy over a large surface area under the transducer array so as to have negligible 
effect on tissues outside the focus. Because of the high temperatures achieved in the high 
intensity focus, sonications are generally limited in duration to only a few seconds.  This reduces 
the potentially detrimental thermal smearing and energy dissipation effects to surrounding tissue 
due to blood perfusion. Because of these technical issues, ablation of a typical tumor requires 
sequential tiling of multiple sonications to create homogeneous thermal damage and coagulative 
necrosis of the entire target volume [16, 17]. 
With focused ultrasound systems, tissue in the path of the ultrasound beams outside the focus is 
warmed, but only to sub-lethal temperatures. Between successive sonications, the heat deposited 
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in intervening tissue is dissipated by normal tissue conduction and perfusion cooling effects [18]. 
Due to the low thermal conductivity and high ultrasound attenuation in the periosteum and bone 
cortex, it is possible to use lower energy levels when treating bone compared to treatment of 
well-perfused soft tissue.  This provides an improved safety profile by reducing thermal damage 
around the treated bone site [19-21]. 
2.1.1. Image-guided FUS   
Over the past decades, there have been numerous external ultrasound array systems for focused 
heating in the body, [22-27] including one system specifically optimized for small animal 
treatments [28]. At present, there are three commercial non-invasive ultrasound heating systems 
that have been integrated within either US or MR imaging systems for image-guidance of FUS 
treatments in humans: the ExAblate system (InSightec Ltd., Tirat Carmel, Israel) based on the 
General Electric MR platform [29, 30]; the Sonalleve FUS system (Koninklijke Philips 
Electronics NV, Eindhoven, The Netherlands) based on the Phillips MR platform [31, 32]; and 
the Haifu system (Model JC, Chongqing Haifu Medical Technology Co. Ltd., Chongqing, 
China) coupled with a B-type ultrasonography system [33]. 
In USgFUS, the US imaging probe is situated in the center of therapeutic transducer array and 
provides real-time sonography feedback. This way, the user can target the lesion to be treated, 
guide the US energy deposition, and assess the extent of acute coagulation necrosis in the treated 
tissue [19, 33, 34]. MRI adds to focused ultrasound therapy the advantages of high resolution 
lesion localization, real time temperature monitoring, and post-treatment tissue evaluation. 
Lesion visualization is achieved through the intrinsic high tissue contrast of MRI, while 
temperature monitoring is achieved through use of specific MRI sequences (proton resonance 
frequency shift method - PRF) performed during the ablation [17].  
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2.2.  Clinical studies 
This review summarizes clinical studies to date assessing use of therapeutic ultrasound for bone 
tumors, including both benign and malignant primary lesions, as well as metastatic disease. Case 
reports were excluded from analysis. In instances of published updates of previous studies, only 
the more complete publications were analyzed. For clinical studies that extend beyond bone 
tumors, only the data regarding bone tumors are presented [34, 35]. The 4th Focused Ultrasound 
Symposium (October 12-16, 2014 in North Bethesda, Maryland USA) reported significant 
advances in the FUS treatment of bone tumors, and abstracts from that recent meeting were 
considered under the aforementioned inclusion criteria. The following sections summarize the 
most relevant aspects of clinical trial design: inclusion criteria for patient selection, endpoints, 
and instruments for outcome assessment.  
2.2.1. Inclusion criteria for patient selection 
For safe and effective ablation therapy, carefully defined patient selection criteria are critically 
important. The anatomy of the human skeleton necessarily involves many critical neighboring 
structures. Patients with bone tumors in difficult to access locations or in close proximity to 
major nerves, e.g. spinal tumors, have been typically excluded from clinical studies. Some 
studies also excluded patients with tumors that are: larger than 10 cm [19], close to the joints 
[36], close to blood vessels [33], in weight-bearing bones [18, 20], or with locally advanced 
disease [35].  
Patients with bone metastases were included in published studies only if they reported moderate 
or severe pain, typically a score of 4 or greater out of 10 for worst pain in a 24-hour period. 
Furthermore, patients with more than 1-2 metastatic sites were excluded since this type of pain is 
believed to be better treated with a systemic rather than focal approach [4]. In the case of 
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MRgFUS, MR compatibility must be considered and patients with claustrophobia or pacemakers 
were excluded from this image guidance technique. Some studies aimed for primary treatment, 
so patients with previous radiotherapy were excluded [37].  
The Karnofsky Performance Status Scale is widely used to quantify the functional status of 
cancer patients [38]. One study in particular did not consider patients with a Karnofsky score 
lower than 70% [19]. Finally, some patients were enrolled only if there was no other treatment 
technique available or feasible [18-21, 33, 35].  
2.2.2. Endpoints and instruments for outcome assessment 
The primary endpoints of a clinical study are typically safety (Phase I) and efficacy (Phases II 
and III). Safety is assessed by occurrence of adverse events, which can be divided into minor and 
major complications [39]. The definition of efficacy is dependent on the type of tumor and intent 
of treatment. For primary bone tumors, either malignant or benign, efficacy is analyzed in terms 
of local tumor control, survival, recurrence, and/or conservation of the diseased-limb. On the 
other hand, treatments for bone metastases aim for pain palliation and improved quality of life; 
where quality of life is considered a secondary endpoint. Geiger et al. also distinguish technical 
and clinical endpoints [17]. The technical endpoints address short-term complications from the 
FUS procedure, and will be considered under the umbrella of safety. In palliative treatments, 
pain progression is also considered.  
Different instruments were used to quantify each target outcome, including questionnaires for 
pain and quality of life assessment, as well as anatomical imaging (CT, MRI, or CE-MRI), 
functional imaging (PET/CT, SPECT, or scintigraphy), biochemical (e.g. alkaline phosphatase) 
and histopathology analyses for determination of response. Each clinical study used one or more 
of these instruments to evaluate clinical outcome. 
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Safety 
The safety endpoint is evaluated in terms of incidence and severity of complications due to the 
FUS treatment. These adverse events must be assessed by clinical and imaging examinations, 
where the latter are especially relevant to detect occult adverse events. Some authors (e.g. [19]) 
subdivide this endpoint into minor and major complications, where the latter are events that lead 
to substantial morbidity, disability, increased level of care, or results in hospital admission or 
substantially lengthened hospital stay [40]. We standardized this classification for all studies. 
Local tumor control 
Local tumor control is generally accessed via imaging (SPECT, MRI or PET/CT), and may also 
be assessed with biochemistry and histopathology analysis. Several parameters can be analyzed: 
inflammatory status; bone remodeling and/or remineralization; tumor vascularity and perfusion; 
tumor cellular survival and activity; coagulative necrosis of the target area, and particularly 
tumor size. For primary malignant bone tumors, the presence and condition of metastatic lesions 
are also evaluated, e.g., using chest radiography and/or CT to define lung metastases [19]. 
Furthermore, biochemical markers for cancer are also assessed in all clinical studies that address 
primary malignancies [19, 33, 34]. To evaluate treatment efficacy via local tumor control, lesion 
changes were evaluated by Napoli et al. [37] in accordance with the MD Anderson (MDA) 
criteria [41]. These criteria include quantitative and qualitative assessments of the behavior of 
bone metastases. The response is divided into four categories: complete response (CR), partial 
response (PR), progressive disease (PD), and stable disease (SD). Quantitatively, these criteria 
define PR as a decrease of 50% or more in the sum of the perpendicular measurements of a 
lesion and PD as an increase of 25% or more in this sum. 
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Pain palliation 
Patient response to treatment was measured by using the Brief Pain Inventory (BPI), a validated 
numeric scale for the evaluation of pain in cancer patients [42]. In this evaluation, patients were 
asked to rate their worst pain with allowed responses ranging typically from a score of 0 to 10 (0 
= no pain, 10 = pain as bad as you can imagine). Two different names were used for this 11-point 
scale: numerical rating scale (NRS) and visual analog scale (VAS). Geiger et al. [17] also used 
the terminology VAS, but for a 1-10 range. Finally, Li et al. [33] used a 4-point pain scale (0-3) 
named verbal rating scale (VRS). 
Another assessment of palliative therapy is derived from pre- and post-procedural pain as 
defined by the use analgesics [40]. In order to quantify its use, a morphine equivalent daily dose 
(MEDD) intake form was used in some studies [43]. In the case of metastatic tumors, both pain 
scales and MEDD followed the standards published by the International Bone Metastases 
Consensus Working Party (IBMCWP) [44]. This consensus defines a minimum follow-up of 2 
weeks, 1 month, and then monthly until 6 months after delivery of FUS treatment. Longer 
follow-up is considered for patients with prolonged survival. Complete response is defined as a 
pain score of zero (VAS or NRS) at the treated site with no concomitant increase in analgesic 
intake (stable or reducing analgesics in daily oral morphine equivalents). Partial response is 
defined as any of the following: (i) pain reduction of 2 or more at the treated site on a 0–10 scale 
without analgesic increase; (ii) analgesic reduction of 25% or more from baseline without an 
increase in pain.  Pain progression is defined as an increase in the pain score of 2 or more points 
above baseline at the treated site with stable analgesic use, or an increase of 25% or more in 
daily oral morphine equivalent compared to baseline with the pain score stable or 1 point above 
baseline [44].  
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One study [36] did not account for the interference of analgesics in pain, but similarly to 
IMBCWP guidelines, considered a minimum VAS reduction of 3 points to be clinically 
significant. Another study proposed their own guidelines for treatment response based on 
guidance from World Health Organization standard [33].  
Quality of life 
Quality of life (QoL) is considered an important secondary endpoint in the majority of clinical 
studies that address painful bone metastases. Pain interference with daily living is evaluated on a 
0-10 scale (0 = no interference, 10 = completely interferes) with questions concerning general 
activity, mood, ability to walk and work normally, relations with other people, sleep, and 
enjoyment of life [4]. This assessment of functional interference related to pain was monitored 
using different questionnaires. The first is described in the brief pain inventory (BPI-QoL) [42] 
and the second (QLQ- BM22) was developed by the European Organization for Research and 
Treatment of Cancer [45]. 
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3. RESULTS 
The summary of all clinical studies meeting the above criteria is presented in Tables II, III and IV 
for primary benign, primary malignant and metastatic bone tumors, respectively. Based on the 
search criteria, 15 clinical studies were selected, which included both USgFUS and MRgFUS 
treatments. The average treatment time was 2 hours, ranging from 2 minutes [35] up to 18h [19]. 
The procedure time was in part dependent on the type of anesthesia or conscious sedation, but 
also on tumor size and blood supply. The number of treatments per site varied: the majority being 
a single treatment and occasionally 2 treatments for both benign tumors and metastatic tumors. 
Primary malignant tumors required up to 7 sessions [19, 33, 46]. Details on treatment planning of 
image-guided FUS are outside the scope of this review, and can be found elsewhere for MRgFUS 
[16] and USgFUS [33]. 
3.1. Primary benign bone tumors 
In 2013, Napoli et al. reported on the use of MRgFUS to treat six patients with limited joint 
function and reduced quality of life due to painful osteoid lesions [47]. These patients were 
included in a recent 24 month follow-up, which included a total of 29 patients with osteoid 
osteoma [17, 48]. Patients received therapy using MRgFUS, delivered toward the nidus, 
identified on MRI and/or CT. The treatment was well tolerated and no adverse events were 
recorded with follow-up up to 24 months. Complete clinical response occurred in 27/29 patients 
as defined by absence of pain and no intake of analgesics. VAS decreased dramatically in these 
patients: from 7.9 at baseline to 0.7 on average at the last follow-up (12-24 months). Two patients 
reported pain recurrence with average VAS=5 requiring subsequent CT-guided radiofrequency 
ablation. Imaging evaluation with CE-MRI demonstrated edema and hyperemia decrease in every 
lesion associated with complete response. At CT, bone remodeling was evident in all complete 
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responders, and nidus fading was demonstrated in 15/27 patients. No complications were 
observed.  
Arrigoni and his colleagues [49] treated 12 painful epiphyseal benign bone lesions with 
MRgFUS. After the treatment, 11 patients had pain regression with a mean VAS that decreased 
from 7.8 to 2.1 on average, 12 months after treatment. A patient with periosteal chondroma did 
not experience improvement. With 12 month follow-up, 8 patients did not show any signs of 
edema on MRI. No substantial changes were found in CT images, but in 3 cases they observed a 
recovery of the normal morphological structure of bone. No major complications were observed. 
From March 2013 to May 2014, 7 consecutive patients with superficial osteoid osteomas of the 
lower limb were treated with MRgFUS [50]. The mean VAS at the baseline was 7.5. In all 
patients VAS dropped to 0 after 1 month. In 6 patients VAS remained at 0 during the follow-up, 
while in 1 patient VAS dropped from 9 to 0 after 1 month, but rose to 2 after 3 months (6-month 
control available, no recurrence documented). No adverse events were observed.  
3.2. Primary malignant bone tumors  
The first FUS treatment performed in bone was in China, in a tibial osteosarcoma on December 
1997. Through October 2001, a total of 1038 patients with solid tumors had undergone 
extracorporeal USgFUS ablation in 10 Chinese hospitals. 153 were bone tumors and 44 were 
reported [34]. Among them, FUS was performed as a limb-salvage treatment in combination with 
neoadjuvant chemotherapy in 34 patients (Enneking’s stage IIb). The remaining ten patients were 
stage IIIb (nine patients with lung metastasis) and were treated with FUS alone with palliative 
intent. Histopathological examination demonstrated clear evidence of tumor destruction and 
regrowth of normal bone in the treated region. Follow-up diagnostic imaging revealed that there 
was no, or reduced, blood supply, and no uptake of radioisotope in the FUS treated tumor, both 
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indicating a positive therapeutic response and absence of viable tumor (no response rate 
available). Furthermore, both CE-MRI and bone scans indicated complete coagulation necrosis of 
the treated tumors. At 6-12 month follow-up, imaging showed obvious regression of the lesion 
and the region of induced coagulation necrosis. Most frequently, the nonenhancing treated 
volume decreased by less than 20-50% in volume. The follow-up range was 10-40 months, and 
the overall survival rate was 85% (38/44). One patient with stage IIb disease, and five patients 
with stage IIIb disease died as a result of distant metastases. Five patients underwent amputation 
due to local recurrence. Few major complications were observed during follow-up period (8%), 
including pathological fractures in three patients, peripheral nerve damage in two, restricted joint 
movement in one, and epiphyseal separation in another one. 
Li et al. evaluated 13 patients diagnosed with primary bone tumors, primarily osteosarcomas, 
treated with USgFUS [33]. At a 6 month follow-up, PET/CT and SPECT showed no abnormal 
radioactivity concentrations in the tumor areas; the areas became cold lesions of the size and 
shape of the original bone tumor. The pain was quantified in a scale ranging from 0-3, and 
decreased, on average, from 1.85 at baseline to 0.08 at the follow-up. The response rate for 
patients with primary bone tumors was significant: 6 (46%) patients had CR, 5 (38%) had PR, 1 
(8%) had moderate response, and 1 (8%) had PD. The overall response rate was 85%. The 1-, 2-, 
3-, and 5-year overall survival rates were 100%, 85%, 69%, and 39%, respectively. No 
abnormalities in electrocardiogram, liver, and kidney functions and blood electrolytes were 
detected. After two months, alkaline phosphatase and lactic acid dehydrogenase returned to 
normal levels [33]. 
In 2010, Chen et al. reported long-term follow-up results of a non-randomized clinical trial [19]. 
The group used USgFUS for the treatment of 80 primary malignant tumors, including 60 stage 
IIb and 20 stage IIIb (Enneking staging) patients. FUS combined with chemotherapy was 
16 
 
performed in 62 patients with osteosarcoma, 1 with periosteal osteosarcoma and 3 with Ewing's 
sarcoma. The remaining 14 patients with chondrosarcoma, malignant giant cell tumor of bone, 
sarcoma of the periosteum or with unknown histology received FUS alone. Follow-up images 
demonstrated complete ablation of the tumors in 69 patients and greater than 50% tumor ablation 
in the remaining 11 patients. The overall 5-year survival rate was 51%, with 64% and 16% for 
patients with stage IIb and III disease, respectively. Among the patients with stage IIb disease, 
long-term survival rates were substantially improved in 30 patients that received combined 
treatment with FUS and chemotherapy (86% 5-year survival rate), in comparison with the 
survival rates for 24 patients that did not finish chemotherapy and six patients who underwent 
partial ablation only (36% 5-year survival rate). Only five of the 69 patients who underwent 
complete ablation had local cancer recurrence during the follow-up period (5-87 months). All 
patients experienced mild pain and among other adverse events, 28% were major complications 
[39], where 11 of these patients required surgery and 8 presented severe peripheral nerve damage. 
In these cases, the distance between the damaged nerves and the tumor margin was less than 10 
mm, suggesting that 10 mm is a reasonable safety margin to avoid nerve damage in FUS 
treatments. 
The most recent USgFUS malignant bone tumor treatment series reported in literature was in 
2013, by Wang et al. [46].  Eleven patients with primary malignant tumors of the bony pelvis 
received USgFUS for both palliative (7 patients) and curative purposes (4 patients). The efficacy 
of FUS ablation was only assessed by CE-MRI. With median follow-up of 22 months (11-154 
months), seven patients that received palliative ablation died of metastatic disease. Enlargement 
of residual tumor was observed in all patients receiving palliative FUS ablations 6-24 months 
after study entry. The remaining four patients that received ablation with curative intent were 
alive at the time of the publication. Local recurrence was observed in one patient receiving 
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curative FUS ablation, which was retreated by additional FUS ablation; no local recurrence was 
observed thereafter. Significant coagulative necrosis was obtained in all patients, with an average 
volume ablation ratio of 87% (range 65-100%). Complete tumor necrosis was achieved in all 
patients receiving curative FUS ablation. No major complications were encountered.  
3.3. Metastatic bone tumors  
Liberman et al. in 2009 published the first multicenter clinical study on the use of FUS for pain 
palliation of bone metastases [21]. This report includes previous pioneer work from [18] and 
[20], comprising 31 patients and 32 bone lesions. 3-month follow-up was available for 25 out of 
31 patients. Eighteen patients (72%) had a significant reduction in pain (>2 points) and 9 (36%) 
reported a VAS score of 0. The average VAS score decreased from 5.9 prior to treatment to 1.8 at 
the 3-month follow-up; with 52% of patients reporting substantial pain relief within 3 days. 
Twenty-four percent had no response and one patient (4%) experienced worsened pain levels. A 
reduction in opioid usage was reported in 67% of patients with recorded medication data. No 
major complications were reported. 
Li et al. also reported on 12 patients with bone metastases treated with USgFUS [33].  96% of the 
patients suffered pain before the procedure. Pain decreased from 1.75 at baseline to 0.17 on a 0-3 
scale at the last follow-up (4-6 months). Response rates were classified by MRI or PET/CT and 
not pathologically: 5 (42%) complete response, 4 (33%) partial response, 1 (8%) had progressive 
disease, with the overall response rate as 75%. The 1-, 2-, 3-, and 5-year overall survival rates 
were 83%, 17%, 0%, and 0%, respectively.  
Napoli et al., in 2013, reported a prospective, single-arm research study with 18 patients treated 
with MRgFUS for painful bone metastases [37]. The pain severity score changed significantly 
from a baseline average of 7.1 to 1.1 at 3-month follow-up. A score of 0 for pain severity, 
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without medication intake, was reported by 13/18 patients (72%) at final follow-up, consistent 
with a complete response to treatment. CT examinations demonstrated increased bone density 
with restoration of cortical borders in 5/18 patients (28%). According to the MDA criteria [41], a 
complete response to treatment was observed in 2/18 patients (11%), a partial response in 4/18 
patients (22%), stable disease in 10/18 patients (56 %) and progressive disease in 2/18 patients 
(11%). No treatment-related adverse events were recorded during the study. 
The results of the first phase III clinical trial on bone tumors were published in 2014 by Hurwitz 
et al. [43]. 147 patients with metastatic bone pain, typically refractory to radiation and other pain 
interventions, were randomized to MRgFUS treatment or placebo treatment. Patients randomized 
to placebo underwent the same procedure as those receiving MRgFUS treatment but without 
energy deposition. The pain response rates three months after treatment were 64% in the 
MRgFUS treated arm versus 20% in the placebo arm. Complete pain relief was observed in 23% 
of treated patients, compared to 6% of patients who received placebo treatment. Approximately 
two-thirds of responders experienced significant pain relief - as defined as a decrease in worst 
NRS score by 2 points or more - within three days of treatment, establishing the ability of 
MRgFUS to induce fast pain response. This response was accompanied by a similarly rapid 
improvement in patient function scores. The most common complication was pain during 
MRgFUS treatment (32%) and major complications (third degree skin burn, fracture) occurred in 
4% of treated patients. However, one fracture was outside the treated area, and the skin burn was 
due to a violation on the inclusion criteria protocol. Furthermore, the majority of adverse events 
(60%) were transient and resolved on the treatment day and 51 patients (46%) had no adverse 
events.  
In 2014, Huisman and colleagues reported the first experience with volumetric MRgFUS for 
palliative treatment of painful bone metastases [51]. In this technique, the focal spot is iteratively 
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switched to well-separated positions around a circular trajectory and sonications are repeated 
continuously till ablative temperatures are achieved throughout increasing diameter concentric 
circles. The resulting volumetric temperature rise contrasts with more traditional raster scan 
iterative sonications where each overlapping focal ablation is followed by a cooling period. The 
goal is improvement in ablation zone homogeneity, energy efficiency, and overall treatment time 
[52]. Pain inventories were implemented at 3 days and 1 month after treatment for 11 patients. At 
3 days after volumetric MR-FUS ablation, NRS pain scores decreased significantly from 8 to 6 
on average, and a response was observed in a 6/11 patients (55%). At 1-month follow-up, 9 
evaluable patients had NRS pain scores decreased significantly compared to baseline from 8 to 4 
on average and 6/9 patients obtained pain response. The overall response rate was 67% with 0% 
pain recurrence at 1-month follow-up. No treatment-related major complications were observed. 
The phase III trial as reported by Hurwitz et al. was subject recently to a retrospective analysis of 
the safety of combination MRgFUS with active systemic chemotherapy [53]. Chemotherapy data 
were available for 104 patients. Patients were followed for 3 months. Ninety patients were treated 
without chemotherapy, and fourteen were treated with chemotherapy. There was no significant 
difference between the response rates of the chemotherapy group (71%) and the non-
chemotherapy group (68%). The overall adverse event rates were 57% for chemotherapy patients 
and 45% for non-chemotherapy patients. Sonication pain was not significantly different between 
the groups, with 50% pain in the chemotherapy group and 28% pain in the non-chemotherapy 
group. Remaining adverse event rates were not significantly different (p=0.17). 
A prospective, single arm, multicenter study was performed to evaluate the efficacy of MRgFUS 
for pain palliation of bone metastasis in patients who had exhausted radiotherapy or refused other 
therapeutic options [54]. 72 patients with painful bone metastases were enrolled. 34/72 patients 
(47%) reported complete response to treatment and discontinued medications. 29/72 patients 
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(40%) experienced a pain score reduction >2 points, consistent with partial response. The 
remaining 9 patients (13%) had recurrence after treatment. Significant differences between 
baseline (6) and follow-up (2) average VAS values and medication intake were observed. 
Similarly, a significant difference was found for QLQ-BM22 between baseline and follow-up 
(p<0.05). No treatment-related adverse events were recorded. 
Finally, Bazzocchi et al. evaluated the clinical outcome of 39 patients (57 lesions) with painful 
bone metastases that were treated with MRgFUS [55]. Nine patients had a single bone metastasis, 
while 5 of them showed no other distant metastasis. The follow-up schedule included 1-, 3-, 6-, 
and 12-month evaluations. Forty-five lesions were evaluated after 1 month, while 31 lesions 
reached the 3-month (54%), 17 the 6-month (30%) and 8 the 12-month (14%) follow-up point. 
Four patients died during follow-up and 3 lesions required retreatment. On a lesion-based 
approach, average VAS score at baseline was 5.2 decreasing to 2.5 at 1 month, and to 2.0, 2.1, 
and 1.2 after 3, 6 and 12 months respectively. In 14/45 lesions (31%) the VAS dropped to 0 one 
month after the treatment; VAS persisted at the 0 level in 8 patients up to 3 months, in 5 patients 
up to 6 months, and in 3 patients up to 12 months. The major determinant of MRgFUS success 
was lesion size, with smaller lesions corresponding to higher efficacy in terms of pain relief - 
possibly due to more efficient tumor debulking. Two treatment-related adverse events were 
reported: a single case of small skin burn, and one case of prostate inflammation in a patient 
treated to the ichiopubic ramus. 
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4. DISCUSSION 
The use of image-guided FUS has increased significantly in the past decade. The ability to 
deliver treatments accurately and non-invasively is a great advantage of image-guided FUS for 
the treatment of bone tumors. Contrary to ionizing radiation, image-guided FUS treatments can 
be repeated without the risk of cumulative dose effects in normal tissues outside the target. Also, 
thermal dose may be confined precisely to a small treatment volume (typically 0.2-20 mm3) 
without the need for invasive implants like microwave, radiofrequency, laser, and cryoablation 
techniques (Table I). Furthermore, the extent of treatment is readily controlled in three 
dimensions, which provides safe non-invasive conformal treatments that spare healthy tissue.  
Efficacy 
Standardization of validated assessment instruments facilitates comparisons of clinical studies. In 
this respect, the IBMCWP guidelines are seeing increasing use for evaluation of palliative 
treatments, which allows direct comparison of treatment outcomes. However, not all studies 
followed the same criteria, making comparison more challenging. For instance, Geiger et al. 
(2014) used a 10-point pain scale (1-10), Li et al. (2010) a 4-point pain scale (0-3), while the 
remaining studies used the IBMCWP 11-point pain scale (0-10). In the case of curative 
treatments, there are greater challenges comparing different studies since the number of patients 
varied widely and different endpoints were reported such as imaging, biochemical analyses, and 
survival rates. Taking into account overall response inclusive of complete and partial responses 
as a baseline for comparisons, the responders group varied within 92-100%, 85-87% and 64-87% 
for primary benign, primary malignant, and metastatic tumors, respectively. In treatments with a 
curative aim the recurrence rate was 0-14%, and in palliative treatments the pain progression was 
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0-13%. These results demonstrate the efficacy of FUS for both palliative and curative purposes in 
the treatment of bone tumors. 
Safety 
Similar to response, challenges exist in assessing safety across studies. Different studies used 
different classifications for adverse events. Therefore, for summary purposes we defined  adverse 
events according to minor and major complications [39]. Overall, studies of benign tumors 
reported 0-66% minor and 0% major complications. Patients treated for primary malignant 
tumors presented higher complication ranges: 45-100% minor and 0-28% major complications. 
Finally, patients with metastatic tumors presented complication ranges similar to the first group: 
0-51% minor and 0-4% major complications. The most frequently observed complications were 
mild skin burn - usually resolving by one-two weeks after FUS - and sonication pain during 
treatment. Several authors inferred that skin burns were most likely due to lack of operator 
experience or not following established protocols. The lack of adverse events in some studies [17, 
37, 47, 48, 50, 54, 55] may relate to the limited number of patients. In clinical studies with large 
number of patients, an USgFUS study [19] reported a major complication rate of 28% (22/80) for 
patients with primary malignant tumors. This was in large part due to lack of guidelines to protect 
normal structures, e.g. there were 8 serious nerve injuries as treatment guidelines did not limit 
proximity to nerves. Other primary malignant studies implemented a 1 cm tumor margin limit 
and major complications were limited to 8%. On the other hand, MRgFUS produced only 4% 
(4/112) major complications in patients with bone metastases. Overall, the data provides strong 
evidence that FUS is safe for treatment of bone metastases and primary benign lesions, while 
other applications are still under investigation.   
Sonication pain was the most common complaint during conscious sedation or epidural 
anesthesia. General anesthesia provides an advantage in terms of alleviation of sonication pain. 
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Also, it ensures intraoperative immobilization which facilitates ultrasound targeting. However, 
the use of anesthesia does not allow patient feedback on pain and that could risk serious normal 
tissue damage [33]. As such, the optimization of patient anesthesia relative to complication rates 
requires further investigation, especially in treatment sites near critical tissue structures. 
US vs MR guidance 
Both MR and US imaging have been used to guide FUS in the treatment of bone tumors. Both 
imaging methods have advantages and disadvantages. Ultrasound imaging devices are less 
expensive, widely available, capable of real-time visualization, and clinically proven in the 
treatment of organs such as liver and kidney which move with respiration. The main disadvantage 
of US is poorer imaging resolution than MRI, especially in areas that have air or bone. 
Furthermore, nerves cannot be visualized by ultrasound imaging, and are thus difficult to avoid in 
the beam path. This is especially relevant because nerves are sensitive to ultrasonic energy and 
tumors are often located adjacent to nerves.  
MRI can provide three-dimensional imaging with better resolution, which allows accurate tumor 
delineation. Also, MR allows continuous monitoring of temperature distribution within the 
treatment zone and thus measures both normal and target tissue temperature rise during FUS 
exposure. Since rapid protein denaturation occurs above 60°C, sonications lead quickly to 
coagulative necrosis which is readily imaged by MR. The combination of these features  - high 
resolution pre-treatment target visualization, MR thermometry during treatment to spare adjacent 
healthy tissue, and immediate post-treatment verification of effective treatment zone - makes MR 
guidance a highly attractive component of focused ultrasound therapy.  
Despite the advantages, MR adds high cost, long treatment time, and problems in tracking 
moving targets, e.g. ribs, which may limit application of MRgFUS. MR temperature imaging is 
limited primarily to the soft tissues adjacent to bone since the PRFS method does not work well 
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to calculate temperature rise in low water content bone cortex, bone marrow and fat tissue. 
However, the received thermal feedback is sufficient to allow control of actual sonication 
location and minimization of damage to non-target tissues [21]. This approach affords the 
treating physician a ‘closed loop’ monitoring of the treatment in real time, resulting in a high 
level of safety and efficacy [18]. Also, the reduced major complications associated with 
MRgFUS will reduce the overall hospitalization time. Thus, although more expensive initially, 
MRgFUS can decrease overall patient care cost [17]. In any case, direct comparison of safety and 
efficacy between MRgFUS and USgFUS is not possible since USgFUS was used mainly for 
primary malignant tumors whereas MRgFUS was used for benign and metastatic tumors. The 
only study on bone metastases was a subset from Li et al. [33] which did not show significant 
differences in terms of adverse events and response rates.  
Future directions 
The success of FUS ablation in the clinical studies summarized above demonstrates the promise 
of image-guided FUS and suggests further investigation is needed in larger numbers of patients 
with primary and secondary bone tumors. Three clinical trials are currently recruiting to evaluate 
MRgFUS in pain palliation of bone metastases: NCT01833806, NCT01964677 and 
NCT01586273. Other aspects could be addressed such as the correlation between site of 
metastases or primary tumor type and treatment outcome, local effect on the progression of bone 
metastases, long-term durability of pain palliation, and long-term durability of bone strength. 
Furthermore, the low procedure morbidity and short treatment time suggests that MRgFUS may 
also be a viable treatment option for patients with multifocal bone metastases. As pointed out by 
Gianfelice and his colleagues [20], treatment for multifocal disease can be repeated with no 
obvious increase in treatment morbidity. Expansion of indications for FUS inclusive of spinal 
treatments whether invasive [56] or non-invasive will significantly expand the number of patients 
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that may benefit from this treatment modality. Finally, additional randomized studies for 
malignant lesions using multimodality approaches including FUS are warranted.   
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5. CONCLUSIONS  
Focused ultrasound is a treatment modality with both emerging and established roles in treatment 
of bone tumors. While most research has focused on MR guidance, both MR and US guidance 
have been studied with promising results. As phase III trials are yet to be completed for treatment 
of primary tumors, further study is warranted, particularly for primary malignant tumors, before 
FUS can be considered standard of care across all clinical applications related to bone lesions. 
Comprehensive review of studies to date, however, indicates that use of FUS to treat primary 
benign tumors, primary malignant tumors, and metastatic tumors is both safe and effective.     
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Table I. Thermal ablation techniques for bone cancer treatement.  
Bone Tumor USgFUS MRgFUS RFA MWA Laser ablation Cryoablation 
Primary malignant 
osteosarcoma 
[19, 33, 34, 46] - - [57] [58] - 
Other primary  
malignant tumors 
[19, 33, 34, 46] [5, 19, 33, 46, 49] [59] [60] - [61] 
Primary benign  
osteoid osteoma 
- [17, 48, 50] [62, 63] [64] [65] [66] 
Other primary  
benign tumors 
- [67] [68-71] [72] - [73] 
Bone metastasis [33] [16, 18, 20, 21, 36, 43, 53-55] [74, 75] [76] - [77] 
 
Abbreviations for Tables II-IV: MR, magnetic resonance; US, ultrasound; IBMCWP, International Bone Metastasis Consensus 
Working Party; VAS, Visual Analogue Scale; VRS, Verbal Rating Scale; NRS, Numeric Rating Scale; QoL, Quality of Life; BPI, 
Brief Pain Inventory; MDA criteria, MD Anderson criteria; OR, overall response; CR, complete response; PR, partial response; PP, 
pain progression; NR, no response; RR, recurrence; AE, adverse event; SR, survival rate. 
 
Table II. Clinical studies of image-guided FUS for primary benign bone tumors. 
Study  Patients  Primary Tumor Endpoints  Device + 
Guidance 
Follow-up  Outcome 
assessment  
Outcome (a= average, m = 
months, y = years) 
Napoli 
2014 [48] 
Geiger 
2014 [17] 
29 Osteoid osteoma Palliation, 
Efficacy, 
Safety, 
ExAblate
+ MR 
1, 6, 12, 24 
months 
IBMCWP 
guidelines, 
Imaging 
93% CR, 7% PP (12-24m) 
aVAS = 7.9 → 0.7 (12-24m)  
0% AE (24m) 
 
Arrigoni  
2014 [49] 
12 Fibro-osteitis (7) 
Periosteal 
chondroma (2) 
Others (3) 
Palliation, 
Efficacy 
ExAblate
+ MR 
6, 12 
months 
VAS, 
Imaging  
92% OR, 8% NR, 0% PP (12m) 
aVAS =  7.8 → 2.1 (12m) 
AE: 66% minor, 0% major 
(12m) 
Bazzocchi 
2014 [50] 
7 Osteoid osteoma Palliation, 
Safety,  
QoL 
ExAblate
+ MR 
1,3, 6, 12 
months 
VAS, QoL 86% CR, 14% PR, 0% PP (1-
12m) 
aVAS =  7.5 → 0.3 (1-12m)  
0% AE (1-12m) 
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Table III. Clinical studies of image-guided FUS for primary malignant bone tumors. 
Study  Patients  Primary Tumor Endpoints  Device + 
Guidance 
Follow-up  Outcome 
assessment  
Outcome (a= average, m = 
months, y = years) 
Wu 2004 
[34] 
44 Malignant (44) 
Stage IIb (34) 
Stage IIIb (10) 
Palliation 
(Stage IIIb),  
Limb 
conservation 
(Stage IIb), 
Safety, 
Survival 
JC Haifu + 
US 
10-39 
months 
Kaplan-Meier 
method, 
Biochemical 
analysis, 
Amputation 
rate, AE 
11% RR (lead to amputations) 
AE: 45% minor, 8% major (1-12m) 
SR: 85% (10-39m) 
 
Li 2010 
[33] 
13 Osteosarcoma (12) 
Fibrous Histiocytoma 
(1) 
Palliation,  
Safety, 
Survival 
JC Haifu + 
US 
1,4,6 
weeks, 4 
,6 months 
VRS, AE, 
Imaging, 
Biochemical 
analysis   
85% OR, 8% RR (4-6m) 
46% CR, 39% PR (4-6m) 
aVRS 1.85 →0.08 (4-6m) 
AE: 68% minor, 0% major (4-6m)   
SR: 100% (1y), 85% (2y), 69% 
(3y), 39% (5y)  
Chen 
2010 [19] 
80 Osteosarcoma (63) 
Other sarcomas 
(13) 
Others (4) 
 
Efficacy, 
Safety, 
Survival 
JC Haifu 
+ US 
1,2,3,4,5 
years 
Kaplan-Meier 
method, 
Imaging, 
Blood 
analysis, AE 
86% CR, 14% NR (2-8w) 
6% RR (2y), 12% RR (5y)  
AE: 100% minor, 28% major (5y)  
SR: 90% (1y), 72% (2y), 61% (3y), 
51% (4y) and 51% (5y) 
Wang 
2013 [46] 
11 Osteosarcoma (4) 
Ewing’s sarcoma (2) 
Chondrosarcoma (2) 
Others (3) 
Palliation, 
Local tumor 
control 
JC Haifu 
+ US 
1,3, 6, 
every 6 
months 
Imaging  87% OR (1d), 0% RR and 0% PP at 
the time of publication 
AE: 100% minor, 0% major 
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Table IV. Clinical studies of image-guided FUS for painful bone metastases. 
Study  Patients  
(lesions) 
Primary 
Tumor 
Endpoints  Device + 
Guidance 
Follow-up  Outcome 
assessment  
Outcome (a= average VAS, m = months, 
y = years) 
Liberman 
2009 [21] 
31 (32) Breast (11) 
Kidneys (6) 
Prostate (5) 
Others (9) 
Palliation, 
Safety  
ExAblate
+ MR 
3 days,  
2 weeks,  
1, 3, 6 
months 
IBMCWP 
guidelines  
72% OR, 4% PP (3m) 
36% CR, 36% PR, 24% NR (3m) 
aVAS = 5.9 → 1.8 (3m) 
AE: 0% (3m) 
Li 2010 
[33] 
12 Liver (5) 
Lung (4) 
Kidney (1) 
Others (2) 
Palliation,  
Safety, 
Survival 
JC Haifu 
+ US 
1, 4, 6 
weeks,  
4, 6 months 
VRS, 
Imaging, 
Biochemica
l analysis   
75% OR, 8% PP (4-6m) 
42% CR, 33% PR (4-6m)  
aVRS = 1.75 → 0.17 (4-6m) 
SR: 83% (1y), 17%  (2y), 0% (3y) 
AE: 68% minor, 0% major (4-6m)   
Napoli 
2013 [37] 
18 Lung (5) 
Breast (4) 
Kidney (3) 
Others (6) 
Palliation, 
Local tumor 
control  
ExAblate
+ MR 
1,3, 6 
months 
IBMCWP 
guidelines, 
BPI, MDA 
criteria  
89% OR (3m) 
72% CR, 17% PR, 11%  PP (3m) 
aVAS = 7.1 → 1.0 (3m) 
AE: 0% (3m) 
Hurwitz  
2014 [43] 
112 Breast (34) 
Lung (17) 
Prostate (15) 
Others (44) 
Palliation, 
Safety, QoL 
ExAblate
+ MR 
2, 5, 7, 14, 
30, 60, 180 
days 
IBMCWP 
guidelines, 
BPI  
64% OR, 23% CR (3m) 
aNRS reduced 3.6 points (3m) 
AE: 51% minor, 4% major (3m) 
60% of AEs solved in 1d 
Huisman 
2014 [51] 
11 (12) Kidney (3) 
Colorectal (3) 
Breast (2) 
Others (3) 
Safety, 
Efficacy, 
Technical 
feasibility 
Sonnallev
e+MR 
3 days,  
1 month 
IBMCWP 
guidelines 
67% OR (1m) 
11% CR, 56% PR, 0%  PP (1m) 
aVAS = 8 → 4 (1m) 
AE: 18% minor, 0% major (1m) 
Meyer 2014 
[53] 
104 Subset from 
Hurwitz et  
al, 2014 
Efficacy, 
Safety  
ExAblate
+ MR 
3 months IBMCWP 
guidelines, 
BPI 
Responders, AE, Sonication pain: 
68%, 45%, 28% (FUS) 
71%, 57%, 50% (FUS+chemo) 
Zaccagna 
2014 [54] 
72 (87) Not provided Palliation, 
QoL 
ExAblate
+ MR 
1, 3 6 
months 
IBMCWP 
guidelines, 
QLQ-BM22 
47% CR, 40% PR, 13% PP (6m) 
aVAS = 6 → 2 (6m) 
AE: 0% (6m) 
Bazzocchi 
2014 [55] 
39 (57) Breast (15) 
Kidney (5) 
Others (18) 
Palliation, 
Safety, QoL 
ExAblate
+ MR 
1, 3, 6, 12 
months 
VAS 
AE 
aVAS = 5.2 → 1.2 (12m) 
VAS = 0 (1m) in 31% patients 
AE: 5% minor, 0% major (12m) 
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